中国抗体(03681.HK)内地总部建设正式开工
中国抗体(03681.HK)公布,全资附属公司杏联药业於11月20日在苏州工业园区上市企业产业园举行新基地开工仪式,标志着中国抗体内地总部建设正式开工。
中国抗体计划未来两年内投入10亿元建设杏联药业新基地以作为公司内地总部,总建筑面积超过7万平米,包括生产车间、中试车间、研发中心、质检中心、临床研究中心及行政大楼等,建成产能约3.8万升的生物反应车间;计划2022年底整体土建竣工,基地建成後可年产单抗注射液 250至300万瓶。(el/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.